First vaccine developed against grass pollen allergy

January 18, 2018, Medical University of Vienna
Approval of the vaccine scheduled for 2021. Credit: Medical University of Vienna

Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm Biomay AG, MedUni Vienna researchers at the Institute of Pathophysiology and Allergy Research have now shown in a Phase II-b study with 180 patients in 11 European centres, that four injections of the synthetically manufactured vaccine BM32 in the first year and a top-up in the second year of treatment relieve the sufferers' symptoms by at least 25 percent.

Immunotherapy with BM32 is based on an innovative recombinant peptide-carrier technology, which requires far fewer injections and has fewer side-effects than other immunotherapies for allergy sufferers. This technology was developed at the Christian Doppler Laboratory for Allergy Research at MedUni Vienna, under the direction of Rudolf Valenta, in collaboration with Viennese partner company Biomay AG (CEO: Rainer Henning). This company specialises in discovering and developing innovative allergy therapeutics.

Revolutionary Viennese product

The vaccine that is used and the requisite antibodies can be synthetically manufactured. This involves extracting the B-cell-reactive peptides from the allergen using a technology developed in Vienna. These peptides are modified so that they lose their bonding properties for allergen-specific IgE and serve as carrier proteins for the necessary support from T-cells. "This process can be repeated an infinite number of times but the vaccine retains its efficacy, is always of equal quality and safe," explains Valenta. "This is a Viennese product that will revolutionise the treatment of grass pollen allergies." The Medical University of Vienna has transferred the patent for production to Biomay AG.

On average, there was a 25 percent improvement in symptoms. "The more severely the sufferer is affected by , the greater the beneficial effect following vaccination," explains Verena Niederberger-Leppin from MedUni Vienna's Department of Ear, Nose and Throat Diseases and lead author of the study, which has now appeared in the Journal of Allergy and Clinical Immunology. The researchers are assuming that the symptoms will diminish even further if the vaccination is topped up for a period of years (the available data relates to a study period of two years). Moreover, it could potentially also be used preventatively.

Approval of the vaccine scheduled for 2021

A follow-on Phase III study and a simultaneous child vaccination study in compliance with all applicable guidelines is scheduled to start in 2019, to create the pre-requisites for general approval of the vaccine from 2021.

At the same time, the investigations into the efficacy of BM32 have shown that the might also be an effective treatment for hepatitis B and could also bring relief to asthma patients. The MedUni Vienna researchers and experts at Biomay AG believe that other potential applications of BM32 are the treatment of allergies to dust mites, cats and ragweed pollen.

Explore further: Grass pollen allergy vaccine also effective against hepatitis B

More information: Verena Niederberger et al. Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32, Journal of Allergy and Clinical Immunology (2018). DOI: 10.1016/j.jaci.2017.09.052

Related Stories

Grass pollen allergy vaccine also effective against hepatitis B

September 8, 2016
A new type of vaccine against grass pollen allergies (BM32) might also offer an effective treatment for combating hepatitis B infection. This is the finding of a study conducted at MedUni Vienna's Institute for Pathophysiology ...

Successful phase IIB trial with third-generation grass pollen allergy vaccine BM32

January 26, 2017
Biomay, a global leader in allergy immunotherapy, announced today that a second Phase IIb study (clinicaltrials.gov identifier NCT02643641) has been successfully completed with its third generation grass pollen allergy vaccine ...

Researchers report innovative grass pollen allergy vaccine

June 2, 2015
Biomay, a global leader in allergy immunotherapy, announced today that the results of a landmark phase IIb study with its 3rd generation grass pollen allergy vaccine BM32 will be reported at the EAACI Congress 2015 in Barcelona, ...

'Apple allergy': Symptoms could be significantly reduced with apple-allergen treatment

October 19, 2012
The food allergy associated with birch pollen is a condition commonly found alongside an allergy to birch pollen. Sufferers are plagued by swelling and reddening or itching in the mouth and throat area, for example when they ...

On the road to allergy prophylaxis

April 14, 2016
Researchers of MedUni Vienna succeeded in binding allergens to endogenous, endogenic white blood corpuscles to trigger a tolerance reaction in case of a future, possible contact with the respective allergen. The results in ...

Study reveals using synthetic peptides could be a better solution for grass allergy sufferers

February 23, 2017
A new approach to treating grass allergies offers potential as a shorter and more effective alternative to traditional allergy shots, according to a recent study led by Queen's researcher Dr. Anne Ellis (Medicine, Biomedical ...

Recommended for you

Immunity connects gut bacteria and aging

November 13, 2018
Over the years, researchers have learned that the different populations of bacteria that inhabit the gut have significant effects on body functions, including the immune system. The populations of gut bacteria are sometimes ...

Probiotics increase bone volume in healthy mice

November 13, 2018
A widely-used probiotic stimulates bone formation in young female mice, according to a study published November 13th in the journal Immunity. In response to treatment with Lactobacillus rhamnosus GG (LGG), other intestinal ...

An enzyme in immune cells plays essential role in host defense against tuberculosis

November 13, 2018
Using freshly resected lung tissue from 21 patients and two distinct mouse models, tuberculosis researchers at the University of Alabama at Birmingham and the Africa Health Research Institute, or AHRI, have identified a protein ...

Study shows changes in histone methylation patterns in nutritionally stunted children

November 13, 2018
An international team of researchers has found changes in histone methylation patterns in nutritionally stunted children. In their paper published in Proceedings of the National Academy of Sciences, the group describes their ...

New clues to the origin and progression of multiple sclerosis

November 13, 2018
Mapping of a certain group of cells, known as oligodendrocytes, in the central nervous system of a mouse model of multiple sclerosis (MS), shows that they might have a significant role in the development of the disease. The ...

Cognitive decline—radiation—brain tumor prevented by temporarily shutting down immune response

November 13, 2018
Treating brain tumors comes at a steep cost, especially for children. More than half of patients who endure radiation therapy for these tumors experience irreversible cognitive decline, a side-effect that has particularly ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.